Notícias Aclaris Therapeutics Inc - ACRS | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (ACRS) Notícias

Aclaris Therapeutics Inc (ACRS)

4,18

0,22

( 5,56% )

Atualizado: 16:14:01

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Form 8-K - Current report

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Aclaris Therapeutics

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições